Altered liver function test after Covid-19 vaccines: A retrospective control group study
- PMID: 37715471
- DOI: 10.1002/pds.5696
Altered liver function test after Covid-19 vaccines: A retrospective control group study
Abstract
Background and purpose: Liver injury after Covid-19 vaccine has been described, although the incidence was not well established. We aimed to compare cumulative incidence of new onset liver test alteration after Covid-19 vaccination, and to compare with an historical control of influenza vaccination.
Methods: We conducted a retrospective cohort study which included adults who received at least one dose of Covid-19 vaccine from January 1 to May 30, 2021 and a control group who received a single dose of influenza vaccine during 2019, in a tertiary medical center from Argentina.
Results: We included 29 798 patients in Covid-19 vaccine group and 24 605 in influenza vaccine group. Liver function tests were performed in 7833 (26.9%) in Covid-19 vaccine group and 8459 (34.37%) in influenza vaccine group. Cumulative incidence at 90 days of new onset liver enzyme test alteration was 4.7 per 1000 (95% 4.0-5.5) for Covid-19 group, and 5.1 per 1000 (95% 4.3-6.1) for the influenza vaccine group (p value = 0.489). Two patients in the Covid-19 vaccine group developed immune mediated liver injury.
Conclusions: We found no difference in liver test alteration between groups. These findings support the safety of Covid-19 vaccines. While we have identified two cases that are consistent with immune mediated liver injury following COVID-19 vaccination, we believe that the available data is insufficient to attribute them solely to the vaccination.
Keywords: Covid-19 vaccination; altered liver function test; autoimmune hepatitis; chemical and drug induced liver injury; inactivated vaccine; influenza vaccines.
© 2023 John Wiley & Sons Ltd.
References
REFERENCES
-
- van Gemeren MAJ, van Wijngaarden P, Doukas M, de Man RA. Vaccine-related autoimmune hepatitis: the same disease as idiopathic autoimmune hepatitis? Two clinical reports and review. Scand J Gastroenterol. 2017;52(1):18-22. doi:10.1080/00365521.2016.1224379
-
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
-
- Marjot T, Webb GJ, Barritt AS 4th, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348-364. doi:10.1038/s41575-021-00426-4
-
- Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. doi:10.1101/2020.02.03.931766
-
- Swissmedic. Side Effects of COVID-19 Vaccines in Switzerland-Update. Accessed October 31. 2021 https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/n...
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical